Researchers Identify Three New IgAN Diagnostic Markers
The identified gene biomarkers show high accuracy in computational models, but require validation in larger patient groups.
Updated on Oct. 23, 2026 in Biotech
Researchers have identified three specific gene biomarkers—A2M, C3AR1, and SERPINA1—as potential diagnostic indicators for immunoglobulin A nephropathy (IgAN). The findings, currently in the research stage, utilized machine learning models to analyze transcriptomic data from human tissue samples.
Why it matters
Complement-related molecular markers for IgAN are currently poorly defined, limiting early detection. This research provides a new computational framework to identify candidate genes that may eventually assist in non-invasive diagnostic workflows.
The study identified 25 complement-related genes, with A2M, C3AR1, and SERPINA1 demonstrating consistent expression patterns and AUC scores exceeding 0.7. An artificial neural network (ANN) classifier integrating these markers achieved an external validation AUC of 0.959.
The details
Researchers integrated bulk transcriptomic datasets and single-cell RNA sequencing data to map gene activity. They employed machine-learning feature selection algorithms—including LASSO, a statistical method that improves prediction accuracy; SVM-RFE, which identifies relevant variables by repeatedly removing weak features; and Boruta, a random-forest-based feature ranking tool—to isolate candidates. Preliminary validation was conducted via quantitative real-time PCR (qRT-PCR) to measure expression levels in five IgAN patients versus five healthy controls.
Timeline
October 23, 2026: Article publication
The Tech Race
This study follows the precedent set by human transcriptomic tissue atlas programs by integrating multi-omics data to define disease-specific biomarkers. It contributes to a competitive field of computational pathology where machine-learning classifiers compete to achieve higher diagnostic specificity in renal disease.
These findings are currently limited to research-stage discovery and cannot yet be used for clinical testing or patient diagnostics. Clinicians and researchers should monitor future studies for validation in larger, annotated populations to determine if these markers can be translated into routine labs.
The takeaway
The study establishes a robust candidate set for IgAN diagnostics, though its clinical application remains theoretical until prospective validation is complete. Watch for follow-up studies in larger cohorts to see if these gene signatures maintain their predictive accuracy outside of computational training sets.
Further reading
Explore more developments in genetic diagnostics within the Biotech section.
More information
View the complete Peer-reviewed research article for detailed methodology.
Source note: This article includes information reported by Nature.
